1. Home
  2. PCSA vs NCL Comparison

PCSA vs NCL Comparison

Compare PCSA & NCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

HOLD

Current Price

$0.27

Market Cap

14.7M

Sector

Health Care

ML Signal

HOLD

Logo Northann Corp.

NCL

Northann Corp.

HOLD

Current Price

$0.34

Market Cap

13.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCSA
NCL
Founded
2011
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.7M
13.1M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
PCSA
NCL
Price
$0.27
$0.34
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$1.00
N/A
AVG Volume (30 Days)
1.1M
111.2K
Earning Date
11-06-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$12,997,205.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.15
$0.30
52 Week High
$1.50
$12.16

Technical Indicators

Market Signals
Indicator
PCSA
NCL
Relative Strength Index (RSI) 48.05 38.19
Support Level $0.27 $0.30
Resistance Level $0.30 $0.41
Average True Range (ATR) 0.02 0.05
MACD 0.00 -0.00
Stochastic Oscillator 62.34 31.62

Price Performance

Historical Comparison
PCSA
NCL

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

About NCL Northann Corp.

Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. It offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, mainly through its sales network in North America and Europe.

Share on Social Networks: